Immunotherapy has revolutionized cancer treatment, yet response rates remain highly variable across tumor types and individual patients. Increasing evidence ...

Dear Dr. Roach: I was recently diagnosed with superficial spreading melanoma. I had a wide excision and was told to follow up with a dermatologist. The dermatologist says to follow up every six months ...

A breakthrough personalized mRNA cancer vaccine that trains the immune system to target patients' unique tumor mutations is showing promising results. Five-year trial data show the risk of recurrence ...

Credit: Getty Images Known as the “great masquerader,” amelanotic melanoma may resemble a variety of benign lesions, thereby increasing diagnostic complexity. Depending on disease stage and risk ...

New results from a clinical trial co-led by UCLA investigators demonstrate how treating desmoplastic melanoma, a rare and aggressive skin cancer, with immunotherapy before surgery can dramatically ...

What if the earliest signs of skin cancer could be identified sooner—before a dermatology appointment? Researchers at the University of Missouri are exploring how artificial intelligence could help ...

An experimental drug custom-made to target the genetic mutations of individual tumors showed promise in treating aggressive skin cancer, according to new results from a clinical trial announced ...

Staging means finding out how far melanoma has spread in the body. Providers group melanoma into stages I (1) through IV (4), with stage I melanoma being the least advanced and stage IV melanoma being ...

Using less ipilimumab appears to make melanoma immunotherapy both safer and more effective, with dramatically better response and survival outcomes. The findings suggest that reducing side effects may ...

Please provide your email address to receive an email when new articles are posted on . New treatments for lung cancer and melanoma have significantly improved OS, but also have exacerbated ...

In the CheckMate 238 trial, patients with resected stage IIIB–C or stage IV melanoma who were treated with nivolumab had longer recurrence-free survival than those who received ipilimumab. Data were ...